<DOC>
	<DOCNO>NCT01636908</DOCNO>
	<brief_summary>The purpose study determine intratumoral concentration kinase inhibitor upon 2 week treatment tumor tissue patient .</brief_summary>
	<brief_title>Determination Intratumoral Concentrations Kinase Inhibitors Patients With Advanced Solid Malignancies .</brief_title>
	<detailed_description>Patients cohort-wise treat clinically available kinase inhibitor 2 week prior standard palliative treatment . Five patient include eight drug cohort . Biopsies perform determine intratumoral drug concentration compare tissue ( phospho ) proteomic kinase activity profile therapy .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Advanced solid malignancy minimum age 18 year indication palliative treatment measurable disease least one lesion accessable biopsy Cardiovascular condition include congestive heartfailure NYHA class &gt; 2 recent myocardial infarction uncontrolled coronary artery disease cardiac arrhythmia require antiarrhythmic therapy uncontrolled hypertension uncontrolled infection serious nonhealing wound , ulcer bone fracture pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>